Patents by Inventor Eliezer Van Allen

Eliezer Van Allen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT RESPONSE
    Publication number: 20220389519
    Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint therapies.
    Type: Application
    Filed: May 27, 2022
    Publication date: December 8, 2022
    Inventors: Eliezer Van Allen, Diana Miao
  • Biomarkers predictive of anti-immune checkpoint response
    Patent number: 11377697
    Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint therapies.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: July 5, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Eliezer Van Allen, Diana Miao
  • PBRM1 biomarkers predictive of anti-immune checkpoint response
    Patent number: 11377696
    Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint therapies.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: July 5, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Eliezer Van Allen, Diana Miao, Toni K. Choueiri
  • CLINICAL INTERPRETATION OF GENOMIC AND TRANSCRIPTOMIC DATA AT THE POINT OF CARE FOR PRECISION CANCER MEDICINE
    Publication number: 20210166782
    Abstract: Feature-based clinical interpretation of whole exome and transcriptome data for precision cancer medicine is provided. In various embodiments, genomic data of a subject is received. The genomic data comprises somatic mutations. A plurality of features is determined from the genomic data of the subject. A similarity metric is determined between the plurality of features and each of a plurality of reference genomes. One or more potentially actionable feature is determined from the similarity.
    Type: Application
    Filed: April 12, 2019
    Publication date: June 3, 2021
    Inventors: Eliezer Van Allen, Brendan Reardon, Nathaniel Moore
  • BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT RESPONSE
    Publication number: 20190338370
    Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint therapies.
    Type: Application
    Filed: January 9, 2018
    Publication date: November 7, 2019
    Inventors: Eliezer Van Allen, Diana Miao
  • PBRM1 BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT RESPONSE
    Publication number: 20190338369
    Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint therapies.
    Type: Application
    Filed: January 3, 2018
    Publication date: November 7, 2019
    Inventors: Eliezer Van Allen, Diana Miao, Toni K. Choueiri
  • Activating JAK Kinase Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response
    Publication number: 20170115291
    Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint inhibitor therapies.
    Type: Application
    Filed: May 28, 2015
    Publication date: April 27, 2017
    Inventors: Kwok-Kin Wong, David Barbie, Eliezer Van Allen